Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, et al.
Nature Reviews Clinical Oncology (2016) Vol. 13, Iss. 11, pp. 674-690
Open Access | Times Cited: 2359

Showing 1-25 of 2359 citing articles:

Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Yixiao Feng, Mia Spezia, Shifeng Huang, et al.
Genes & Diseases (2018) Vol. 5, Iss. 2, pp. 77-106
Open Access | Times Cited: 1147
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro, Nancy U. Lin, Kornélia Polyák
Cancer Discovery (2019) Vol. 9, Iss. 2, pp. 176-198
Open Access | Times Cited: 1052
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 91-113
Closed Access | Times Cited: 769
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang, Ding Ma, Chen Suo, et al.
Cancer Cell (2019) Vol. 35, Iss. 3, pp. 428-440.e5
Open Access | Times Cited: 740
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou, Olmo Sonzogni, Mateus de Oliveira Taveira, et al.
Cancer Discovery (2019) Vol. 9, Iss. 6, pp. 722-737
Open Access | Times Cited: 530
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Sylvia Adams, Sherene Loi, Deborah Toppmeyer, et al.
Annals of Oncology (2018) Vol. 30, Iss. 3, pp. 405-411
Open Access | Times Cited: 525
Breast Cancer: Current Perspectives on the Disease Status
Mohammad Fahad Ullah
Advances in experimental medicine and biology (2019), pp. 51-64
Closed Access | Times Cited: 498
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, et al.
Cancer Cell (2021) Vol. 39, Iss. 12, pp. 1578-1593.e8
Open Access | Times Cited: 477
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Lei Ding, Jiaqi Cao, Wen-Shan Lin, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 1960-1960
Open Access | Times Cited: 445
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 10, pp. 1360-1372
Open Access | Times Cited: 433
Metformin and Its Benefits for Various Diseases
Ziquan Lv, Yajie Guo
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 408
Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation
Xin Liang, Xinyu Ye, Chao Wang, et al.
Journal of Controlled Release (2019) Vol. 296, pp. 150-161
Closed Access | Times Cited: 349
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Jessica N. Spradlin, Xirui Hu, Carl C. Ward, et al.
Nature Chemical Biology (2019) Vol. 15, Iss. 7, pp. 747-755
Open Access | Times Cited: 346
Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer
Wei Li, Takashi Tanikawa, Ilona Kryczek, et al.
Cell Metabolism (2018) Vol. 28, Iss. 1, pp. 87-103.e6
Open Access | Times Cited: 341
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
Yue Gong, Peng Ji, Yun‐Song Yang, et al.
Cell Metabolism (2020) Vol. 33, Iss. 1, pp. 51-64.e9
Open Access | Times Cited: 324
Emerging new therapeutic antibody derivatives for cancer treatment
Shijie Jin, Yanping Sun, Liang Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 315
Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer
Lina Liu, Yuhua Wang, Lei Miao, et al.
Molecular Therapy (2017) Vol. 26, Iss. 1, pp. 45-55
Open Access | Times Cited: 308
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Yacine Barèche, David Venet, Michail Ignatiadis, et al.
Annals of Oncology (2018) Vol. 29, Iss. 4, pp. 895-902
Open Access | Times Cited: 297
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao, Ding Ma, Shen Zhao, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 16, pp. 5002-5014
Open Access | Times Cited: 295
Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism
Ji‐Young Lee, Ali E. Yesilkanal, Joseph Wynne, et al.
Nature (2019) Vol. 568, Iss. 7751, pp. 254-258
Open Access | Times Cited: 292
Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication
Wen Song, Jing Kuang, Chu‐Xin Li, et al.
ACS Nano (2018) Vol. 12, Iss. 2, pp. 1978-1989
Closed Access | Times Cited: 284
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, et al.
CA A Cancer Journal for Clinicians (2021) Vol. 72, Iss. 2, pp. 165-182
Open Access | Times Cited: 267
Breast Cancer Treatments: Updates and New Challenges
Anna Burguin, Caroline Diorio, Francine Durocher
Journal of Personalized Medicine (2021) Vol. 11, Iss. 8, pp. 808-808
Open Access | Times Cited: 263
Mitochondrial copper depletion suppresses triple-negative breast cancer in mice
Liyang Cui, Arvin M. Gouw, Edward L. LaGory, et al.
Nature Biotechnology (2020) Vol. 39, Iss. 3, pp. 357-367
Open Access | Times Cited: 262
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Antonio Marra, Dario Trapani, Giulia Viale, et al.
npj Breast Cancer (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 254
Page 1 - Next Page

Scroll to top